There's a way to find out, you know? 🤪

They do when the "crush" is a fall worse than expected.

Stock prices drop on bad NEWS.

The end of Humira patents in early 2023 is not news at all.

It's been well known and discussed for years, so the effects have been baked into analysts' earnings expectations for years.

The company has a good product line-up and pipeline as their management has been forewarned that Humira won't go on forever.

On the contrary, I read that AbbVie might actually cling on to part of their Humira business with longer running patents indirectly connected with the drug.

Disclaimer: I bought the stock after it was beaten down on announcing the Allergan takeover, so I'm long ABBV. It's done very well since then - and if I'd been worried about the long known impending fizzling of Humira profits, I would have sold.

Edit: typo

No. You just didn't understand my reply.

In my experience, most people who post a buying target of 69 at a share price of 122 will not strike at 69 but reduce their "buying target" to 33 $. It's like the types who go to car dealers not to make a purchase but only to kick tyres...